Cocrystal Pharma Inc. | Ownership
Companies that own Cocrystal Pharma Inc.
LSP Advisory BV
1,012,025
3.38%
104,695
10.44%
06/30/2018
Wasatch Advisors, Inc.
505,914
1.69%
505,914
0.01%
06/30/2018
Millennium Management LLC
410,286
1.37%
410,286
0%
06/30/2018
Emory University (Investments)
152,916
0.51%
0
0.35%
06/30/2018
KeyBank, NA (Investment Management)
78,009
0.26%
78,009
0%
06/30/2018
Goldman Sachs & Co. LLC (Private Banking)
41,503
0.14%
41,503
0%
06/30/2018
BlackRock Fund Advisors
29,812
0.1%
29,812
0%
06/30/2018
Jane Street Capital LLC
21,444
0.07%
21,444
0%
06/30/2018
The Vanguard Group, Inc.
20,600
0.07%
20,600
0%
06/30/2018
Northern Trust Investments, Inc.
17,300
0.06%
17,300
0%
06/30/2018
| Address |
19805 North Creek Parkway
Bothell Washington 98011
United States
|
|
Employees
|
- |
| Website |
http://www.cocrystalpharma.com |
| Updated |
07/08/2019 |
| Cocrystal Pharma, Inc. is a clinical stage biotechnology company, which engages in discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of Hepatitis C. Phase 1b studies in Hepatitis C infected patients showed the largest reduction in viral load of any non-neoside inhibitor tested to date. |
